Last reviewed · How we verify

bolus of intravenous ketamine

Ciusss de L'Est de l'Île de Montréal · FDA-approved active Small molecule

bolus of intravenous ketamine is a NMDA receptor antagonist Small molecule drug developed by Ciusss de L'Est de l'Île de Montréal. It is currently FDA-approved for Induction and maintenance of general anesthesia, Acute pain management and analgesia, Sedation in critical care settings.

Ketamine is a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that produces rapid-onset anesthesia and analgesia.

Ketamine is a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that produces rapid-onset anesthesia and analgesia. Used for Induction and maintenance of general anesthesia, Acute pain management and analgesia, Sedation in critical care settings.

At a glance

Generic namebolus of intravenous ketamine
SponsorCiusss de L'Est de l'Île de Montréal
Drug classNMDA receptor antagonist
TargetNMDA receptor
ModalitySmall molecule
Therapeutic areaAnesthesia, Analgesia, Psychiatry
PhaseFDA-approved

Mechanism of action

Ketamine blocks NMDA glutamate receptors on neurons, particularly at the phencyclidine binding site within the ion channel pore. This antagonism interrupts excitatory neurotransmission and produces dissociative anesthesia, analgesia, and sedation. When administered as an intravenous bolus, it achieves rapid onset of action suitable for acute clinical settings.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about bolus of intravenous ketamine

What is bolus of intravenous ketamine?

bolus of intravenous ketamine is a NMDA receptor antagonist drug developed by Ciusss de L'Est de l'Île de Montréal, indicated for Induction and maintenance of general anesthesia, Acute pain management and analgesia, Sedation in critical care settings.

How does bolus of intravenous ketamine work?

Ketamine is a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that produces rapid-onset anesthesia and analgesia.

What is bolus of intravenous ketamine used for?

bolus of intravenous ketamine is indicated for Induction and maintenance of general anesthesia, Acute pain management and analgesia, Sedation in critical care settings, Treatment-resistant depression (emerging indication).

Who makes bolus of intravenous ketamine?

bolus of intravenous ketamine is developed and marketed by Ciusss de L'Est de l'Île de Montréal (see full Ciusss de L'Est de l'Île de Montréal pipeline at /company/ciusss-de-l-est-de-l-le-de-montr-al).

What drug class is bolus of intravenous ketamine in?

bolus of intravenous ketamine belongs to the NMDA receptor antagonist class. See all NMDA receptor antagonist drugs at /class/nmda-receptor-antagonist.

What development phase is bolus of intravenous ketamine in?

bolus of intravenous ketamine is FDA-approved (marketed).

What are the side effects of bolus of intravenous ketamine?

Common side effects of bolus of intravenous ketamine include Dissociation and hallucinations, Increased heart rate and blood pressure, Nausea and vomiting, Dizziness and vertigo, Emergence reactions, Respiratory depression.

What does bolus of intravenous ketamine target?

bolus of intravenous ketamine targets NMDA receptor and is a NMDA receptor antagonist.

Related